Collectively, these findings suggest that PTPN22 could represent another promising therapeutic target in CLL, as reducing the amount or activity of this phosphatase would be expected to reprogram signals that increase leukemic cell survival into signals that induce leukemic cell death. The gene discussed is PTPN22; the disease is B-cell chronic lymphocytic leukemia.